Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
20 05 2021
Historique:
received: 12 04 2021
revised: 09 05 2021
accepted: 11 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 9 11 2021
Statut: epublish

Résumé

Contemporary antiretroviral agents afford enhanced potency and safety for patients living with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in the early stages of the HIV epidemic. While the safety profile has improved, adverse drug reactions still occur. We have segregated the antiretroviral agents used in contemporary practice into class groupings based on their mechanism of antiviral activity (non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, and entry inhibitors) while providing a review and discussion of the hepatoxicity seen in the most relevant clinical literature published to date. Clinical literature for individual agents is discussed and agent comparisons afforded within each group in tabular format. Our review will provide a summative overview of the incidence and medications associated with hepatic adverse reactions linked to the use of contemporary antiretroviral drugs.

Identifiants

pubmed: 34065305
pii: cells10051263
doi: 10.3390/cells10051263
pmc: PMC8160846
pii:
doi:

Substances chimiques

Anti-Retroviral Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

N Engl J Med. 2018 Aug 16;379(7):645-654
pubmed: 30110589
Lancet. 2009 Sep 5;374(9692):796-806
pubmed: 19647866
Lancet. 2004 Apr 17;363(9417):1253-63
pubmed: 15094269
J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48
pubmed: 20404738
Curr Treat Options Infect Dis. 2019;11(4):372-387
pubmed: 33380904
Lancet. 2012 Jun 30;379(9835):2429-2438
pubmed: 22748590
J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506
pubmed: 33136751
Hepatology. 2002 Jan;35(1):182-9
pubmed: 11786975
JAMA. 2000 Jan 5;283(1):74-80
pubmed: 10632283
AIDS Res Hum Retroviruses. 2004 Jul;20(7):698-700
pubmed: 15307912
Lancet. 2007 Jul 7;370(9581):49-58
pubmed: 17617272
Curr HIV Res. 2011 Jan;9(1):40-53
pubmed: 21198432
HIV Med. 2016 Jan;17(1):62-7
pubmed: 26122981
AIDS Patient Care STDS. 2012 May;26(5):259-64
pubmed: 22404426
Lancet HIV. 2020 Jan;7(1):e16-e26
pubmed: 31740348
AIDS. 2010 Nov 13;24(17):2743-50
pubmed: 20935557
Clin Infect Dis. 2010 Feb 15;50(4):605-12
pubmed: 20085491
N Engl J Med. 2008 Jul 24;359(4):355-65
pubmed: 18650513
Antivir Ther. 2009;14(6):859-64
pubmed: 19812449
Lancet. 2011 Jul 16;378(9787):229-37
pubmed: 21763935
Gastroenterol Hepatol (N Y). 2006 Jun;2(6):430-437
pubmed: 28316518
J Infect Dis. 2010 Mar 15;201(6):803-13
pubmed: 20151839
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):3-6
pubmed: 23881239
Antivir Ther. 2017;22(3):215-223
pubmed: 27922453
N Engl J Med. 2020 Mar 26;382(13):1232-1243
pubmed: 32212519
BMJ Open. 2019 Apr 2;9(4):e023140
pubmed: 30944128
J Hepatol. 2006;44(1 Suppl):S132-9
pubmed: 16364487
PLoS One. 2017 Jun 20;12(6):e0179254
pubmed: 28632758
AIDS. 2014 Mar 13;28(5):717-25
pubmed: 24983542
HIV Med. 2013 Jan;14(1):49-59
pubmed: 23088336
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S90-7
pubmed: 14986280
Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):18-21
pubmed: 21492993
Lancet. 2020 Jul 25;396(10246):239-254
pubmed: 32711800
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):463-472
pubmed: 30985556
Clin Infect Dis. 2005 Sep 1;41(5):e45-7
pubmed: 16080074
J Antimicrob Chemother. 2012 Aug;67(8):2020-8
pubmed: 22532465
Lancet HIV. 2020 Jun;7(6):e389-e400
pubmed: 32504574
AIDS. 2011 Sep 10;25(14):1737-45
pubmed: 21716073
HIV Med. 2012 Aug;13(7):427-35
pubmed: 22413938
Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1455-68
pubmed: 19863454
J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558-64
pubmed: 20703158
HIV Clin Trials. 2010 May-Jun;11(3):125-32
pubmed: 20736149
HIV Clin Trials. 2014 Jul-Aug;15(4):151-60
pubmed: 25143024
Lancet. 2012 Jun 30;379(9835):2439-2448
pubmed: 22748591
J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S34-9
pubmed: 14562856
Clin Infect Dis. 2003 Sep 1;37(5):e57-62
pubmed: 12942419
Am J Gastroenterol. 2001 May;96(5):1619-22
pubmed: 11374710
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):79-86
pubmed: 23466649
AIDS. 2014 Feb 20;28(4):613
pubmed: 24469001
AIDS. 2008 Nov 30;22(18):2557-8
pubmed: 19005287
Antivir Ther. 2008;13(2):297-306
pubmed: 18505181
HIV Med. 2012 Feb;13(2):127-31
pubmed: 21599819
Lancet. 2017 Nov 4;390(10107):2063-2072
pubmed: 28867497
Am J Gastroenterol. 1997 Sep;92(9):1563-4
pubmed: 9317091
Clin Liver Dis. 2007 Aug;11(3):615-39, vii-viii
pubmed: 17723923
Lancet. 2007 Apr 7;369(9568):1169-78
pubmed: 17416261
N Engl J Med. 2008 Oct 2;359(14):1429-41
pubmed: 18832244
Lancet HIV. 2017 Apr;4(4):e154-e160
pubmed: 28219610
Drugs Today (Barc). 2020 Jun;56(6):405-421
pubmed: 32525138
Lancet. 2021 Dec 19;396(10267):1994-2005
pubmed: 33308425
J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40
pubmed: 17057609
Curr HIV Res. 2017;15(3):216-224
pubmed: 27774892
J Antimicrob Chemother. 2007 Mar;59(3):342-6
pubmed: 17255142
Lancet. 2011 Jul 16;378(9787):238-46
pubmed: 21763936
Int J STD AIDS. 2019 May;30(6):620-622
pubmed: 30722751
Arch Intern Med. 2000 Jul 10;160(13):2050-6
pubmed: 10888979
AIDS. 1998 May 7;12(7):827-9
pubmed: 9619823
Antimicrob Agents Chemother. 2009 May;53(5):1747-52
pubmed: 19223645
Braz J Infect Dis. 2016 Sep-Oct;20(5):502-4
pubmed: 27054757
J Antimicrob Chemother. 2005 Feb;55(2):280-1
pubmed: 15650005
Antiviral Res. 2001 Nov;52(2):189-98
pubmed: 11672829
J Acquir Immune Defic Syndr. 2006 Sep;43(1):1-5
pubmed: 16936557
AIDS. 2019 Jun 1;33(7):1261-1263
pubmed: 31045944
Antimicrob Agents Chemother. 2008 Mar;52(3):858-65
pubmed: 18070967
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):294-298
pubmed: 27171740
AIDS. 2016 Jan 2;30(1):57-63
pubmed: 26372481
Infection. 2009 Jun;37(3):244-9
pubmed: 19471856
Lancet HIV. 2020 Nov;7(11):e740-e751
pubmed: 33128903
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S80-9
pubmed: 14986279
J Infect Dis. 2008 May 15;197 Suppl 3:S279-93
pubmed: 18447614
Drugs Today (Barc). 2019 Jan;55(1):25-34
pubmed: 30740610
Lancet HIV. 2017 Aug;4(8):e331-e340
pubmed: 28546090
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
AIDS. 2016 May 15;30(8):1267-78
pubmed: 26867136
Arch Intern Med. 2006 Jan 9;166(1):49-56
pubmed: 16401810
Clin Pharmacol Drug Dev. 2019 Jul;8(5):664-673
pubmed: 30811880
J Hepatol. 2005 Jul;43(1):60-6
pubmed: 15922478
Lancet. 2017 Nov 4;390(10107):2073-2082
pubmed: 28867499
Infect Drug Resist. 2018 Apr 26;11:615-623
pubmed: 29731650
J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):78-81
pubmed: 24419064
Clin Infect Dis. 2011 Oct;53(8):807-16
pubmed: 21921224
AIDS Rev. 2013 Jul-Sep;15(3):139-45
pubmed: 24002197
Int J STD AIDS. 2018 Mar;29(4):414-417
pubmed: 29059031
Clin Infect Dis. 2020 Dec 18;:
pubmed: 33336698
Lancet Infect Dis. 2012 Feb;12(2):111-8
pubmed: 22018760
J Antimicrob Chemother. 2002 Nov;50(5):763-5
pubmed: 12407142
Ann Pharmacother. 2003 Sep;37(9):1325-8
pubmed: 12921517
Sex Transm Infect. 2020 Dec;96(8):618-619
pubmed: 31974214
Lancet. 2013 Mar 2;381(9868):735-43
pubmed: 23306000

Auteurs

Ashley O Otto (AO)

Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, USA.

Christina G Rivera (CG)

Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, USA.

John D Zeuli (JD)

Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, USA.

Zelalem Temesgen (Z)

Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH